Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06205823 | Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM(CAREMM-2305) | unknown | — | 1,600 | Seoul St. Mary's HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06201507 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | unknown | Phase 2 | 44 | Beijing Children's HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06203145 | A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM | unknown | N/A | 30 | Peking University First HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04776265 | RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT | unknown | — | 100 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05078840 | PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors | unknown | — | 75 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05308875 | Efficacy and Safety Evaluation of PD1-BCMA-CART | unknown | N/A | 9 | Bioray LaboratoriesINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05420493 | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 | 54 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04090268 | Precision Exercise in Children With Malignant Hemopathies(SportTherapy) | unknown | N/A | 380 | University of Milano BicoccaOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 20 | University Medical Center GroningenOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT06104553 | A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05757466 | Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma(Prolgo-HL) | unknown | Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03617666 | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study(AVENuE) | unknown | Phase 2 | 49 | University College, LondonOTHER | 2 | Dec 12, 2023 | clinicaltrials |
| NCT04727008 | CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma | unknown | Phase 1 | 12 | Sichuan UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06160362 | The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 7, 2023 | clinicaltrials |
| NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | unknown | Phase 2 | 50 | Chunyan Sun, MDOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT06154317 | Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM) | unknown | — | 30 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 118 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT03064269 | CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05803395 | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. | unknown | — | 954 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05114330 | Secondary Central Nervous System Lymphoma Registry - Charité | unknown | — | 300 | Charite University, Berlin, GermanyOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04089215 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | unknown | Phase 2 | 82 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05747157 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04870853 | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy | unknown | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03121456 | 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma(LYMPHODTECT) | unknown | N/A | 74 | Centre Antoine LacassagneOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05998928 | A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy | unknown | Phase 2 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06126237 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 120 | Keymed Biosciences Co.LtdINDUSTRY | 0 | Nov 13, 2023 | clinicaltrials |
| NCT06116734 | Lapelga vs Gastrofil | unknown | Phase 3 | 74 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Nov 3, 2023 | clinicaltrials |
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | unknown | Phase 1 | 22 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04897139 | Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT | unknown | Phase 2 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT06056752 | QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | unknown | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06083701 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | unknown | Phase 1 / Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | unknown | Phase 2 | 98 | Ho Sup LeeOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03697356 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia(Ballondor) | unknown | Phase 2 | 54 | Kosin University Gospel HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT05378971 | Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma | unknown | N/A | 15 | LanZhou UniversityOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04712864 | Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | unknown | Phase 1 | 50 | Legend Biotech USA IncINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT06060080 | Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma | unknown | N/A | 7 | Yao LiuOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04693676 | A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma | unknown | Phase 1 | 17 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06049381 | Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research | unknown | — | 22 | Ruijin HospitalOTHER | 0 | Sep 22, 2023 | clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05979948 | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia(CZ-WM01) | unknown | Phase 2 | 60 | Shanghai Changzheng HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06037239 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jan 16, 2024source: clinicaltrials